Can I stop taking venetoclax/venetoclax once I take it?

Venetoclax/Venetoclax is a selective inhibitor of the BCL-2 protein. It is mainly used to treat a variety of hematological malignancies, including chronic lymphocytic leukemia (CLL) and certain types of acute myeloid leukemia (AML), especially in patients with specific genetic mutations or who are insensitive to traditional treatments.

The mechanism of action of venetoclax is mainly to induce tumor cell apoptosis by inhibiting the function ofBCL-2 protein. BCL-2 is an anti-apoptotic protein that is highly expressed in many malignant tumors and helps cancer cells escape the normal cell death process. By targeting BCL-2, venetoclax reduces the ability of tumor cells to survive, thereby promoting their death. In addition, venetoclax is often used in combination with other chemotherapy drugs to increase the overall effectiveness of treatment and improve patient prognosis.

Regarding the use of venetoclax, once it is started it does not necessarily mean that the patient must take it for life. Treatment regimens with this drug are usually tailored to the patient's specific circumstances, disease progression, and response to treatment. In most cases, the use of venetoclax is based on response and tolerability to treatment, and doctors will regularly evaluate the patient's condition and treatment effects to decide whether to continue use, adjust the dose, or discontinue the drug.

In some clinical practices, patients may experience a better response after treatment with venetoclax, with the attendant possibility of alleviation or remission of the disease. In this case, your doctor may consider tapering or discontinuing venetoclax. However, the discontinuation process must be done with caution and under the guidance of a professional physician, as sudden discontinuation may lead to recurrence or aggravation of the disease.

In addition, long-term use of venetoclax may also lead to certain side effects, such as increased risk of infection, thrombocytopenia, etc. Therefore, during treatment, patients need to regularly monitor blood routine and other related indicators to ensure the safety of treatment. Patients should promptly report any symptoms of discomfort to their doctor while taking venetoclax so that the treatment plan can be adjusted.

Reference materials:https://www.oncolink.org/cancer-treatment/oncolink-rx/venetoclax-venclexta